

Award Number: DAMD17-99-1-9287

TITLE: Role of Diet in the Initiation and Prevention of
Breast Cancer

PRINCIPAL INVESTIGATOR: Amy J. Lewis, Ph.D.
Thomas Walle, Ph.D.

CONTRACTING ORGANIZATION: Medical University of South Carolina
Charleston, South Carolina 29425

REPORT DATE: June 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20001020 038

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2000	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 99 -31 May 00)	
4. TITLE AND SUBTITLE Role of Diet in the Initiation and Prevention of Breast Cancer			5. FUNDING NUMBERS DAMD17-99-1-9287	
6. AUTHOR(S) Amy J. Lewis, Ph.D. Thomas Walle, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Medical University of South Carolina Charleston, South Carolina 29425 E-MAIL: rpasqual@mail.mdanderson.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; Distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)				
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 31
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Appendices	

Progress Report
Assistance Award #DAMD17-99-1-9287
Role of Diet in the Initiation and Prevention of Breast Cancer

The purpose of the above titled postdoctoral traineeship was to complete several tasks focused upon further establishing the role of EST in the bioactivation of the cooked-food mutagen and breast carcinogen N-OH-PhIP and establishing how bioflavonoids may be used to prevent this bioactivation process. Task #1, as outlined in the statement of work, listed several goals to help define the involvement of EST in bioactivation of N-OH-PhIP in the normal human breast cell and tissue. Part of this task, characterizing the expression and localization of EST in normal human breast cells and tissue, has opened many new research opportunities. Although EST had previously been detected in cultured human mammary epithelial cells, EST had never been detected or its localization determined in normal human breast tissue. However, by using immunohistochemistry we have for the first time localized EST to the epithelial cells lining the ducts and alveoli of normal human breast tissue. This finding is not only novel but is interesting in that these very ductal epithelial cells are believed to be the site for tumor initiation by various carcinogens, including the breast carcinogen N-OH-PhIP.

By using a very sensitive technique, immuno-staining with confocal microscopy, we have also determined the subcellular localization of EST in cultured human mammary epithelial cells. We found EST present in the cytosol, as previously described by western blot analysis, but of great excitement was our new finding that EST, maybe even a novel isoform, is localized to the nuclei of these breast cells. The potential biological role of this nuclear EST remains to be determined.

Because of the importance of EST in bioactivation and in estrogen hormone regulation, we felt that the EST localization studies and the potential biological relevance of nuclear and cytoplasmic EST to breast cancer development must be further investigated. Therefore, we have

submitted a *DOD concept grant application* and a *DOD idea grant application* in hopes of obtaining more research funding to continue these studies.

We must mention that in addition to studying the EST localization proposed in Task #1, we also further explored bioactivation of N-OH-PhIP by EST. These results were published in *Carcinogenesis* (article enclosed). In this study we established that EST expression increases with subsequent days following cell seeding, but we have yet to determine how EST expression effects DNA binding of N-OH-PhIP in normal breast cells.

Task #2, outlined in the statement of work, listed several goals to help define the inhibitory role of bioflavonoids on EST activity and EST-mediated binding of cooked-food mutagens to DNA. We have accomplished several goals listed under this task and our findings are currently in press in *The Journal of Steroid Biochemistry and Molecular Biology* (article enclosed). We have established the inhibitory effect of the dietary polyphenols quercetin and resveratrol on EST activity, i.e. 17 β estradiol. Both compounds potently inhibited recombinant human EST in a competitive fashion with K_i values of about 1 μ M. In fact, both polyphenols could serve as substrates for EST. In order to extend the studies we examined whether inhibition of EST also occurred in the intact cultured human mammary epithelial cells. The IC_{50} for resveratrol was very similar to that for recombinant EST, i.e. about 1 μ M. Surprisingly, quercetin was 10 times more potent in the HME cells with an IC_{50} of about 0.1 μ M, a concentration that should be possible to achieve from the normal dietary content of this flavonoid.

Because we have determined that EST catalyzes the bioactivation of the cooked-food mutagen and breast carcinogen N-OH-PhIP, promoting its subsequent binding to DNA, inhibiting EST with quercetin and other dietary flavonoids could serve as a protective mechanism in breast cancer initiation. As we have established the ability of flavonoids to inhibit EST in intact cells using HME cells as a model, we will work on determining if flavonoids can

inhibit EST-mediated bioactivation of N-OH-PhIP using a DNA binding assay.

Overall we feel that the last year has been productive and has resulted not only in publications, but also more importantly in grant applications. The localization studies proposed in Task #1 have given us an opportunity to collaborate and receive input from pathologists and specialist in immunolocalization. Our findings in Task #2 have also led to a side project of trying to understand why Quercetin inhibition of EST in the intact cell is so much more potent compared to the recombinant enzyme. We believe that in the breast cell quercetin may be activated to a more potent form, inhibit synthesis of the cofactor PAPS, or perhaps most likely, inhibit some signaling pathway important for the regulation of EST expression.

Key Research Accomplishments:

- We localized EST to the epithelial cells lining ducts and alveoli of normal human breast tissue using immunohistochemistry. Previously, EST had only been isolated from cultured human breast cells and detected by immunoblot analysis.
- We localized EST to the nuclei of normal human mammary epithelial cells using immunostaining with confocal microscopy. This is a key finding in that nuclear EST may represent a novel EST isoform or EST may have a different subcellular localization than currently believed.
- We determined that EST expression increases with increasing days following cell seeding.
- We have established that the flavonoids quercetin and resveratrol potently inhibit isolated recombinant human EST in a competitive fashion.
- We have established that quercetin and resveratrol also potently inhibit EST activity in the intact human mammary epithelial cells and that the inhibition by quercetin is surprisingly more potent in the intact cell compared to the recombinant enzyme.

Reportable Outcomes:

1. Lewis, AJ, Walle, UK, King, RS, Kadlubar, FF, Falany, CN, and Walle, T. (1998) Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. *Carcinogenesis*, **19**, 2049-2053.
2. Lewis-Nolan, A, Otake, Y, Walle, UK, and Walle, T. (2000). Inhibition of estrogen sulfotransferase in normal human mammary epithelial cells. *Proceedings of the American Association for Cancer Research*. **41**, 836.
3. Otake, Y, Lewis-Nolan A., Walle, UK, and Walle, T. (2000). Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. *The Journal of Steroid Biochemistry and Molecular Biology*. **In press**.
4. *DOD concept grant application*: Estrogen sulfotransferase, a marker for breast cancer progression, submitted 4/12/00
5. *DOD idea grant application*, Estrogen sulfotransferase, a key enzyme in breast cancer development, submitted 6/7/00

SHORT COMMUNICATION

Bioactivation of the cooked food mutagen *N*-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells

Amy J.Lewis, U.Kristina Walle, Roberta S.King¹, Fred F.Kadlubar¹, Charles N.Falany² and Thomas Walle³

Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, ¹National Center for Toxicological Research, Jefferson, AR 72079 and ²Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA

³To whom correspondence should be addressed
Email: walle@muscd.edu

Cooked food mutagens from fried meat and fish have recently been suggested to contribute to the etiology of breast cancer. Thus, the most prevalent of these compounds, i.e. 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine, or rather its more mutagenic *N*-hydroxylated metabolite (*N*-OH-PhIP), forms DNA adducts in mammary cells, including human mammary epithelial (HME) cells. The objective of this study was to determine the involvement of estrogen sulfotransferase (EST), the only sulfotransferase identified in HME cells, in the further bioactivation of *N*-OH-PhIP. These studies were done *in vitro* using human recombinant EST and in intact HME cells. Human recombinant EST increased the covalent binding of [³H]*N*-OH-PhIP to calf thymus DNA ~3.5-fold in the presence of the sulfotransferase co-substrate 3'-phosphoadenosine-5'-phosphosulfate at each *N*-OH-PhIP concentration (1, 10 and 100 µM) (*n* = 6, *P* < 0.001). In contrast, EST did not catalyze the DNA binding of two other cooked food mutagens, *N*-hydroxy-2-amino-3-methylimidazo[4,5-*f*]quinoline and *N*-hydroxy-2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline, which are mainly hepatocarcinogens. Cultured HME cells displayed high EST activity, which could be completely inhibited by 1 µM estrone. When the cells were incubated with [³H]*N*-OH-PhIP, binding to native DNA occurred at 60–240 pmol/mg DNA. This binding was inhibited to 55% of control by 1 µM estrone (*P* < 0.01, *n* = 8), suggesting that EST plays a significant role in carcinogen bioactivation in human breast tissue.

Breast cancer is the second leading cause of cancer-related death in American women (1), yet its etiology remains unknown. Factors such as family history and lifetime exposure to endogenous estrogens account for ~30% of breast cancer cases (2). Studies suggest that exogenous genotoxic carcinogens present in our diet and the environment may contribute to human breast cancer (3). It has been suggested that the highest cancer risks may result from ingestion of fried beef and

fish products (4–6). 2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP), the most prevalent of the heterocyclic amines formed during the cooking process of various meats (4,7), is a mutagen in *Salmonella typhimurium* (8) and Chinese hamster ovarian cells (9,10). *In vivo* PhIP has been shown to induce both colon and mammary tumors in rodents (11,12). Although most studies have focused on the role of PhIP as a colon carcinogen, it also should be important to determine its potential involvement in human mammary tumor initiation.

Several recent studies suggest that normal human mammary epithelial (HME) cells may have the capacity to activate several carcinogens, one being PhIP, to species capable of binding DNA (13–15). In order for PhIP to bind to DNA, it must first be *N*-hydroxylated by cytochrome P450 1A2 (16,17). Furthermore, the *N*-hydroxylated metabolite is then converted to its ultimate carcinogen via phase II metabolizing enzymes, most prominently the acetyltransferases or sulfotransferases (15,18–26).

The finding that HME cells express only one of multiple isoforms of the sulfotransferase family, i.e. estrogen sulfotransferase (EST) (27), was of particular interest. This isoform has substrate specificities similar to that of the phenol form of sulfotransferase (P-PST) (28), previously shown to activate *N*-hydroxy PhIP (*N*-OH-PhIP) (21,25,26). The objective of this study was to determine the ability of EST to sulfate *N*-OH-PhIP and two other cooked food mutagens, *N*-hydroxy-2-amino-3-methylimidazo[4,5-*f*]quinoline (*N*-OH-IQ) and *N*-hydroxy-2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline (*N*-OH-MeIQx), to species capable of binding to DNA. These studies were carried out both *in vitro*, using human recombinant EST, and in cultured HME cells.

[³H]*N*-OH-PhIP (101 mCi/mmol) (20), [³H]*N*-OH-IQ (99 mCi/mmol) and [³H]*N*-OH-MeIQx (130 mCi/mmol) were prepared as previously described (19,29). Ultrapure 3'-phosphoadenosine-5'-phosphosulfate (PAPS) was purchased from S.S.Singer (University of Dayton, Dayton, OH). [³H]PhIP (2.15 Ci/mmol) was obtained from Chemsyn Science Laboratories (Lenexa, KS) through the National Cancer Institute Chemical Carcinogen Reference Standard Repository. All other chemicals were purchased from Sigma (St Louis, MO).

Recombinant human EST was isolated and purified from EST/pKK233-2 XL1-Blue cultures after induction with 1 mM isopropyl-β-D-thiogalactopyranoside for 5 h at 37°C, as previously described (28) with several modifications (30). The isolated enzyme preparation was free of other sulfotransferases but did contain bacterial proteins. Purification of EST to homogeneity was unsuccessful due to instability of the enzyme. The actual concentration of EST is therefore not known. It sulfated its natural substrate β-estradiol with a *K_m* value of 25 nM, which is similar to a previous report (28).

The EST-catalyzed sulfation of the *N*-hydroxylated amines was measured as the PAPS-dependent covalent binding to calf thymus DNA of the labile sulfuric acid ester formed, using radiolabeled substrates, as previously described for P-PST

Abbreviations: EST, estrogen sulfotransferase; HBSS, HEPES-buffered balanced salt solution; HME, human mammary epithelial; *N*-OH-IQ, *N*-hydroxy-2-amino-3-methylimidazo-[4,5-*f*]quinoline; *N*-OH-MeIQx, *N*-hydroxy-2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline; *N*-OH-PhIP, *N*-hydroxy-PhIP; NAT-1, *N*-acetyltransferase 1; PAPS, 3'-phosphoadenosine-5'-phosphosulfate; PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine; P-PST, phenol form of phenolsulfotransferase.

(26). Conditions for the reaction were optimized using 20 nM [^3H] β -estradiol (28). Saturating concentrations of co-substrate were reached at 20 μM PAPS. Sulfation was linear with time up to 60 min and with enzyme up to 6 μl EST preparation.

The typical reaction mixture consisted of calf thymus DNA (2 mg/ml), recombinant human EST and 20 μM PAPS in a final incubation volume of 100 μl 33 mM Tris buffer (pH 7.5). The reactions were initiated with [^3H]N-OH-PhIP, [^3H]N-OH-IQ or [^3H]N-OH-MeIQx (1, 10 and 100 μM) and were incubated at 37°C for 30 min under argon saturation. The radiolabeled drugs were added in dimethyl sulfoxide:ethanol (4:1). Control incubates did not contain the co-substrate PAPS. After incubation, the samples were extracted twice with *n*-butanol saturated with distilled water and once with phenol:chloroform:isoamyl alcohol (25:24:1, pH 8) (Amersco, Solon, OH) with 1 g/l 8-hydroxyquinoline. DNA was then precipitated with 5 M sodium acetate and 100% ethanol. The DNA pellet was washed three times with ethanol, resuspended in Tris buffer and analyzed by liquid scintillation spectrometry. Washes were counted to ensure removal of non-specific binding. DNA recovery was determined by measuring the UV absorbance at 260 nm. On average, 90% of the DNA was recovered.

Primary HME cells, at passage 7, were obtained from Clonetics (San Diego, CA). These cells were derived from a 22-year-old healthy woman who had undergone reduction mammoplasty. Cell cultures were maintained as recommended by Clonetics. Serum-free mammary epithelial growth medium was supplemented with the following (final concentrations): bovine pituitary extract (52 $\mu\text{g/ml}$), human recombinant epidermal growth factor (10 ng/ml), insulin (5 $\mu\text{g/ml}$), hydrocortisone (0.5 $\mu\text{g/ml}$), gentamicin (50 $\mu\text{g/ml}$) and amphotericin-B (50 ng/ml). Experiments were conducted with cells at passage 9–11.

HME cells grown to confluent monolayers on 100 mm plates were washed twice with a HEPES-buffered balanced salt solution (HBSS) of the following composition: 10 mM glucose, 20 mM HEPES, 1.2 mM Na_2HPO_4 , 1.2 mM MgSO_4 , 145 mM NaCl, 5 mM KCl, 2 mM CaCl_2 and NaOH to a pH of 7.4. The cells were then incubated for 4 h at 37°C with 10 μM [^3H]N-OH-PhIP in 5 ml HBSS in the presence or absence of 1 μM estrone. The incubation buffer was removed and cells were lifted by incubating them for 5 min at 37°C in 10 mM Tris buffer (pH 8) containing 1 mM EDTA and 0.14 M NaCl. Cells were collected by centrifugation and incubated overnight at 37°C in 10 mM Tris buffer (pH 8) containing 0.1 M EDTA, 100 $\mu\text{g/ml}$ proteinase K and 0.5% SDS. The mixture was then extracted with 3 vols phenol:chloroform:isoamyl alcohol. DNA and RNA present in the aqueous phase were precipitated with 1 vol cold 100% ethanol and 5 M sodium acetate. The pellet was resuspended in 10 mM Tris buffer (pH 8) containing 0.1 M EDTA and 20 $\mu\text{g/ml}$ pancreatic RNase and incubated for 1 h at 37°C. After extraction with 3 vols phenol:chloroform:isoamyl alcohol, DNA was again precipitated with 100% ethanol, collected by centrifugation and dissolved in water. DNA recovery was determined by UV absorbance at 260 nm. The amount of [^3H]N-OH-PhIP bound to DNA was quantitated by liquid scintillation spectrometry.

Results are expressed as mean values $\pm$ SE. The statistical significance of differences was analyzed by Student's *t*-test for unpaired data. Because of the non-normal distribution of the whole cell data, the Mann-Whitney test was used.

The EST-catalyzed binding of [^3H]N-OH-PhIP to calf




Fig. 1. (A) Binding of increasing concentrations of [^3H]N-OH-PhIP to calf thymus DNA in incubates with 6 μl recombinant human EST. The open bars (Control) are in the absence of the co-substrate PAPS and the closed bars (+PAPS) in the presence of 20 μM PAPS. (B) Binding of 100 μM [^3H]N-OH-PhIP to calf thymus DNA in incubates with increasing amounts of recombinant human EST. Each bar represents binding in the presence of 20 μM PAPS with the control binding, i.e. without PAPS, subtracted. Data are expressed as means $\pm$ SE ($n = 6$). *Significantly higher than for the control ($P < 0.001$).

thymus DNA is shown in Figure 1. Figure 1A shows the binding of increasing concentrations of [^3H]N-OH-PhIP to DNA in incubates containing 6 μl EST. The control binding, i.e. without the co-substrate PAPS, represents non-enzymatic binding of the *N*-hydroxylamine directly to DNA. With catalytically active EST, i.e. in the presence of the co-substrate PAPS, binding of N-OH-PhIP to calf thymus DNA increased ~3.5-fold at each N-OH-PhIP concentration (1, 10 and 100 μM) ($n = 6$ at each concentration; $P < 0.001$). Figure 1B shows the binding of one concentration of [^3H]N-OH-PhIP (100 μM) to DNA at various EST concentrations. The binding increased with increasing enzyme concentrations. Whereas the control binding (without PAPS) stayed the same and was subtracted for each enzyme concentration, the PAPS-dependent binding was linear with amount of enzyme ($y = 6.13x + 3.12$, $r = 1.000$).

2-Naphthylamine is a substrate for sulfoconjugation, resulting in formation of a sulfamate (31). PhIP itself, a primary heterocyclic amine with aromatic properties, might thus also be sulfated without prior oxidation. However, EST possessed no ability to bioactivate [^3H]PhIP to a species capable of binding DNA. There was thus no increased binding to DNA in the presence of PAPS at either 1, 10 or 100 μM [^3H]PhIP ($n = 6$ at each concentration). Not unexpectedly, the background binding of [^3H]PhIP was 20-fold lower compared with [^3H]N-OH-PhIP.

In Figure 2 is shown the binding of [^3H]N-OH-IQ and [^3H]N-OH-MeIQx to calf thymus DNA, using incubation conditions identical to those in Figure 1A. In sharp contrast to N-OH-PhIP, catalytically active EST did not significantly enhance the binding of N-OH-IQ to DNA compared with control incubates. A minimal (15–20%) but statistically significant increase in DNA binding of N-OH-MeIQx in the presence of PAPS and EST was observed at 10 and 100 μM substrate concentrations, but not at 1 μM .

As can be seen in Figure 2, N-OH-MeIQx had similar non-enzymatic background binding as N-OH-PhIP, whereas that for N-OH-IQ was several times higher. This is consistent with a previous study (19). Also, for all three *N*-hydroxylated heterocyclic amines the DNA binding in the absence of EST was identical to that in the absence of PAPS.

These findings suggest that EST plays a role in the conversion of N-OH-PhIP, a potent mammary carcinogen, to a more




Fig. 2. Binding of increasing concentrations of [3 H]N-OH-IQ (A) and [3 H]N-OH-MeIQx (B) to calf thymus DNA in incubates with 6 μ l recombinant human EST. The open bars (Control) are in the absence of the co-substrate PAPS and the closed bars (+PAPS) in the presence of 20 μ M PAPS. Data are expressed as means $\pm$ SE ($n = 6$). *Significantly higher than for the control ($P < 0.001$).

reactive species. It is of interest to notice that N-OH-MeIQx and N-OH-IQ, mainly hepatocarcinogens (32,33), are not further bioactivated by EST. However, these carcinogens may be better substrates for other bioactivating enzymes, such as the acetyltransferases (19,22). The high level of acetyltransferase activity in the liver may play a role in the tissue-specific carcinogenicity of IQ, the most potent rat and primate hepatocarcinogen described (22,33). Conversely, the higher affinity of N-OH-PhIP for EST expressed in normal breast cells may contribute to the tissue-specific carcinogenicity of PhIP in the mammary gland.

In order to assess the importance of EST-catalyzed N-OH-PhIP bioactivation under more physiological conditions, we used intact cultured HME cells as the model system. EST is the only sulfotransferase expressed in these cells, as determined by western blotting (27). The EST activity in HME cells, determined with 20 nM [3 H] β -estradiol as substrate at 6 days after cell seeding, was 5.1 ± 1.0 pmol/mg cellular protein for a 3 h incubation, which is 2–3 times that reported previously at 1 day after cell seeding (27). To be able to use this model system in our studies, a specific EST inhibitor was obligatory. Estrone, by virtue of being another high affinity substrate for EST, provided this tool, producing virtually complete inhibition of β -estradiol sulfation by HME cells at a concentration as low as 1 μ M. Using an established human red blood cell assay (34), estrone did not inhibit NAT-1, the other potential bioactivating enzyme (13), even at a concentration of 1000 μ M.

To assess EST-dependent binding of [3 H]N-OH-PhIP to native DNA of the intact cell, HME cells were treated with 10 μ M [3 H]N-OH-PhIP, the intermediate concentration in Figure 1A, for 4 h in the presence and absence of 1 μ M estrone. Cellular DNA was then isolated and purified as described in Materials and methods and analyzed for incorporation of radiolabeled N-OH-PhIP. Figure 3A shows the EST-catalyzed binding of [3 H]N-OH-PhIP to native DNA of HME cells in eight individual experiments. In all experiments estrone reduced binding of N-OH-PhIP to DNA. Mean binding in the presence of the inhibitor was 55% of control ($P < 0.01$, $n = 8$). The variability between individual experiments appears to reflect a difference in EST expression. Thus, in experiments 5–8, performed in the same batch of cells at 6, 8, 9 and 10 days post-cell seeding, there was an EST-mediated binding of 11.8, 29.0, 58.8 and 160.0 pmol [3 H]N-OH-PhIP/mg DNA, respectively, i.e. markedly increased binding with increased




Figure 3. (A) Binding of 10 μ M [3 H]N-OH-PhIP to native DNA of normal HME cells in eight individual experiments. The closed bars are in the absence of inhibitor and the open bars are in the presence of 1 μ M estrone. (B) EST activity in HME cells at different times after cell seeding in a separate set of experiments. EST activity was measured over 3 h with β -estradiol as substrate.

maturity of the HME cells. A separate set of experiments examined EST expression in the HME cells at various times post-cell seeding. As shown in Figure 3B, there was an almost linear increase in EST activity over days 6–10, correlating well with the increased estrone-inhibitable DNA binding of [3 H]N-OH-PhIP. It is obvious that estrone did not completely inhibit the binding of [3 H]N-OH-PhIP to native HME cell DNA. This non-EST-mediated binding may be attributed to direct binding of [3 H]N-OH-PhIP, as seen in Figure 1A, or its potential oxidation products. It should be noted that the incubations with recombinant EST were carried out under argon to protect the N-OH-PhIP from oxidative degradation, which obviously could not be employed with intact cells. Another contributor to this binding could be bioactivation of N-OH-PhIP by another enzyme, such as acetyltransferase. Sadrieh *et al.* (15), using the 32 P-post-labeling technique, have indeed demonstrated with human mammary gland cytosol, although not with intact HME cells, that *N*-acetyltransferase 1 (NAT-1) *O*-acetylates N-OH-PhIP, increasing its reactivity towards DNA. It therefore appears feasible to postulate that both EST and NAT-1 present in normal human breast cells may further bioactivate N-OH-PhIP, promoting DNA adduct formation that, if unrepaired (13), may lead to tumor initiation.

It is not known if these cooked food heterocyclic amines are hydroxylated in the liver and then transported via the blood to their target sites for further enzymatic activation or if both oxidation and phase II esterification occur at the site of tumorigenicity. Whereas PhIP is the promutagen ingested with cooked foods (8), N-OH-PhIP is derived mainly from cytochrome P450 1A2 oxidation in the body. Although most of this oxidation probably takes place in the liver (16,19), it may also occur in breast cells. It has been suggested that DNA adducts are formed in HME cells when the cells are exposed to the promutagen PhIP (14). Although cytochrome P450 1A2 is not expressed in breast cells, a variety of other cytochrome P450 isoforms have recently been detected (35). In fact, a recent report shows that PhIP is a substrate for cytochrome P450 1B1, a newly described P450 present in normal human breast cells (36).

However, even if the generation of N-OH-PhIP from PhIP is not efficient in breast cells, N-OH-PhIP could be transported from the liver. Further bioactivation could then occur in the breast cells, as previously suggested (13). Although this might include *O*-acetylation (13,15), our present study suggests that this bioactivation also includes sulfation mediated by EST.

It is known that PhIP induces mutations in a tumor suppressor gene, *APC*, associated with colorectal cancer development (7,37). While mutations in various genes, including *ras* and *p53*, have been identified in PhIP-induced mammary tumors (38,39), the principal genes containing mutations are still an area of investigation.

EST is the only human sulfotransferase that has been shown to be hormonally regulated. Using an endometrial adenocarcinoma cell line, Falany and Falany found that progesterone increases EST expression as much as 7-fold (40). During the luteal phase of the menstrual cycle there is a surge in progesterone levels and one may speculate that during this time women may be more susceptible to carcinogen bioactivation through EST.

In conclusion, human EST has been shown to be capable of sulfoconjugating N-OH-PhIP. This reaction was shown to increase the binding of N-OH-PhIP to calf thymus DNA by >3-fold. Extending these studies to the more physiological intact cultured HME cells clearly demonstrated EST-catalyzed binding of N-OH-PhIP to native cellular DNA. As EST is the only sulfotransferase isoform expressed in normal human breast cells, we hypothesize that this reaction significantly contributes to the initiation of breast cancer in humans.

Acknowledgements

The excellent technical assistance of Yoko Otake is gratefully acknowledged. This work was supported by a grant from the National Institutes of Health (CA3386).

References

1. American Cancer Society (1997) *Cancer Facts and Figures*. American Cancer Society, Atlanta, GA.
2. Perera, F.P., Estabrook, A., Hewer, A., Channing, K., Rundle, A., Mooney, L.A., Whyatt, R. and Phillips, D.H. (1995) Carcinogen-DNA adducts in human breast tissue. *Cancer Epidemiol. Biomarkers Prev.*, **4**, 233-238.
3. Biggs, P.J., Warren, W., Venitt, S. and Stratton, M.R. (1993) Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. *Mutagenesis*, **8**, 275-283.
4. Layton, D.W., Bogen, K.T., Knize, M.G., Hatch, F.T., Johnson, V.M. and Felton, J.S. (1995) Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. *Carcinogenesis*, **16**, 39-52.
5. Ronco, A., De Stefani, E., Mendilaharsu, M. and Dencio-Pellegrini, H. (1996) Meat, fat and risk of breast cancer: a case-control study from Uruguay. *Int. J. Cancer*, **65**, 328-331.
6. Järvinen, R., Knekt, P., Seppänen, R. and Teppo, L. (1997) Diet and breast cancer risk in a cohort of Finnish women. *Cancer Lett.*, **114**, 251-253.
7. Gooderham, N.J., Murray, S., Lynch, A.M. et al. (1996) Heterocyclic amines: evaluation of their role in diet associated human cancer. *Br. J. Clin. Pharmacol.*, **42**, 91-98.
8. Malfatti, M.A., Shen, N.H., Wu, R.W., Turteltaub, K.W. and Felton, J.S. (1995) A correlation of *Salmonella* mutagenicity with DNA adducts induced by the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Mutagenesis*, **10**, 425-431.
9. Thompson, L.H., Tucker, J.D., Stewart, S.A., Christensen, M.L., Salazar, E.P., Carrano, A.V. and Felton, J.S. (1987) Genotoxicity of compounds from cooked beef in repair-deficient CHO cells versus *Salmonella* mutagenicity. *Mutagenesis*, **2**, 483-487.
10. Yadollahi-Farsani, M., Gooderham, N.J., Davies, D.S. and Boobis, A.R. (1996) Mutational spectra of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) at Chinese hamster *hprt* locus. *Carcinogenesis*, **17**, 617-624.
11. Ito, N., Hasegawa, R., Sano, M., Tamano, S., Esumi, H., Takayama, S. and Sugimura, T. (1991) A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). *Carcinogenesis*, **12**, 1503-1506.
12. Imai, K., Hagiwara, A., Yada, H., Masui, T., Hasegawa, R., Hirose, M., Sugimura, T., Ito, N. and Shirai, T. (1996) Dose-dependent induction of mammary carcinomas in female Sprague-Dawley rats with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Jpn. J. Cancer Res.*, **87**, 1116-1120.
13. Fan, L., Schut, H.A.J. and Snyderwine, E.G. (1995) Cytotoxicity, DNA adduct formation and DNA repair induced by 2-hydroxyamino-3-methylimidazo[4,5-f]quinoline and 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine in cultured human mammary epithelial cells. *Carcinogenesis*, **16**, 775-779.
14. Carmichael, P.L., Stone, E.M., Grover, P.L., Gusterson, B.A. and Phillips, D.H. (1996) Metabolic activation and DNA binding of food mutagens and other environmental carcinogens in human mammary epithelial cells. *Carcinogenesis*, **17**, 1769-1772.
15. Sadrieh, N., Davis, C.D. and Snyderwine, E.G. (1996) *N*-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. *Cancer Res.*, **56**, 2683-2687.
16. McManus, M.E., Felton, J.S., Knize, M.G., Burgess, W.M., Roberts-Thompson, S., Pond, S.M., Stupans, I. and Veronese, M.E. (1989) Activation of the food-derived mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by rabbit and human liver microsomes and purified forms of cytochrome P-450. *Carcinogenesis*, **10**, 357-363.
17. Zhao, K., Murray, S., Davies, D.S., Boobis, A.R. and Gooderham, N.J. (1994) Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human liver microsomes. *Carcinogenesis*, **15**, 1285-1288.
18. Buonarati, M.H., Turteltaub, K.W., Shen, N.H. and Felton, J.S. (1990) Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine to intermediates which bind DNA. *Mutat. Res.*, **245**, 185-190.
19. Turesky, R.J., Lang, N.P., Butler, M.A., Teitel, C.H. and Kadlubar, F.F. (1991) Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. *Carcinogenesis*, **10**, 1839-1845.
20. Lin, D., Kaderlik, K.R., Turesky, R.J., Miller, D.W., Lay, J.O. Jr and Kadlubar, F.F. (1992) Identification of *N*-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine as the major adduct formed by the food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, with DNA. *Chem. Res. Toxicol.*, **5**, 691-697.
21. Abu-Zeid, M., Yamazoe, Y. and Kato, R. (1992) Sulfotransferase-mediated DNA binding of *N*-hydroxyarylamines(amides) in liver cytosols from human and experimental animals. *Carcinogenesis*, **13**, 1307-1314.
22. Davis, C.D., Schut, H.A.J. and Snyderwine, E.G. (1993) Enzymatic phase II activation of the *N*-hydroxyamines of IQ, MeIQx and PhIP by various organs of monkeys and rats. *Carcinogenesis*, **14**, 2091-2096.
23. Malfatti, M.A., Buonarati, M.H., Turteltaub, K.W., Shen, N.H. and Felton, J.S. (1994) The role of sulfation and/or acetylation in the metabolism of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in *Salmonella typhimurium* and isolated rat hepatocytes. *Chem. Res. Toxicol.*, **7**, 139-147.
24. Kaderlik, K.R., Minchin, R.F., Mulder, G.J., Ilett, K.F., Daugaard-Jensen, M., Teitel, C.H. and Kadlubar, F.F. (1994) Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. *Carcinogenesis*, **15**, 1703-1709.
25. Ozawa, S., Chou, H.-C., Kadlubar, F.F., Nagata, K., Yamazoe, Y. and Kato, R. (1994) Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine by cDNA-expressed human and rat arylsulfotransferases. *Jpn. J. Cancer Res.*, **85**, 1220-1228.
26. Chou, H.-C., Lang, N.P. and Kadlubar, F.F. (1995) Metabolic activation of *N*-hydroxy arylamines and *N*-hydroxy heterocyclic amines by human sulfotransferase(s). *Cancer Res.*, **55**, 525-529.
27. Falany, J.L. and Falany, C.N. (1996) Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. *Cancer Res.*, **56**, 1551-1555.
28. Falany, C.N., Krasnykh, V. and Falany, J.L. (1995) Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. *J. Steroid Biochem. Mol. Biol.*, **52**, 529-539.
29. Enomoto, M., Sato, K., Miller, E.C. and Miller, J.A. (1968) Reactivity of the diacetyl derivative of the carcinogen 4-hydroxyaminoquinoline-1-oxide with DNA, RNA, and other nucleophiles. *Life Sci.*, **7**, 1025-1032.
30. Lewis, A.J., Kelly, M.M., Walle, U.K., Eaton, A.E., Falany, C.N. and Walle, T. (1996) Improved bacterial expression of the human P form phenolsulfotransferase. *Drug Metab. Dispos.*, **24**, 1180-1185.
31. Hernandez, J.S., Powers, S.P. and Weinshilboum, R.M. (1991) Human liver arylamine *N*-sulfotransferase activity: thermostable phenol sulfotransferase catalyzes the *N*-sulfation of 2-naphthylamine. *Drug Metab. Dispos.*, **19**, 1071-1079.
32. Snyderwine, E.G., Turesky, R.J., Turteltaub, K.W. et al. (1997) Metabolism of food-derived heterocyclic amines in nonhuman primates. *Mutat. Res.*, **376**, 203-210.
33. Ohgaki, H., Takayama, S. and Sugimura, T. (1991) Carcinogenicities of heterocyclic amines in cooked food. *Mutat. Res.*, **259**, 399-410.

34. Lee, J., Chung, J., Lai, J., Levy, G. and Weber, W. (1997) Kinetics of arylamine *N*-acetyltransferase in tissue from human breast cancer. *Cancer Lett.*, **111**, 39–50.
35. Huang, Z., Fasco, M.J., Figge, H.L., Keyomarsi, K. and Kaminsky, L.S. (1996) Expression of cytochromes P450 in human breast tissue and tumors. *Drug Metab. Dispos.*, **24**, 899–905.
36. Crofts, F.G., Strickland, P.T., Hayes, C.L. and Sutter, T.R. (1997) Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP) by human cytochrome P4501B1. *Carcinogenesis*, **18**, 1793–1798.
37. Toyota, M., Ushijima, T., Kakiuchi, H., Canzian, F., Watanabe, M., Imai, K., Sugimura, T. and Nagao, M. (1996) Genetic alterations in rat colon tumors induced by heterocyclic amines. *Cancer*, **77** (suppl.), 1593–1597.
38. Snyderwine, E.G. (1996) The food-derived heterocyclic amines and breast cancer: a 1995 perspective. *Recent Results Cancer Res.*, **140**, 17–25.
39. Roberts-Thomson, S.J. and Snyderwine, E.G. (1997) Effect of dietary fat on codon 12 and 13 *Ha-ras* gene mutations in 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine-induced rat mammary gland tumors. *Mol. Carcinogen.*, **20**, 348–354.
40. Falany, J.L. and Falany, C.N. (1996) Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. *Endocrinology*, **137**, 1395–1401.

Received on July 15, 1997; revised on July 7, 1998; accepted on July 17, 1998

THE JOURNAL OF STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY

Steroid Hormone Research Unit
Institut de Puériculture
26 Blvd Brune, 75014 Paris, France

Dr Jorge R. PASQUALINI
Editor-in-Chief

Tel. : (33) (1) 45 39 91 09 / secretary
(33) (1) 45 42 41 21 / direct
Fax : (33) (1) 45 42 61 21

Dr WALLE T.
Dept Cell & Molecular Pharmacology
and Experimental Therapeutics
Medical University of South Carolina
173 Ashley Avenue
PO Box 250505
Charleston
SC 29425
U.S.A.

Paris, 22 March 2000

Paper N°: **JSBMB 99-7254**

Dear Dr Walle,

It is a pleasure to inform you that your manuscript entitled :


QUERCETIN AND RESVERATROL POTENTLY REDUCE ...

by Y. ATAKE *et al.*

is ready for publication in the *JOURNAL OF STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY*. It is being sent to the printers and you should receive the corresponding proofs directly from Elsevier in due course.

The anticipated issue of publication is : JUNE 2000 (Vol 72/6).

Yours sincerely,



Dr J. R. PASQUALINI
Editor-in-Chief

Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells

Yoko Otake, Amy L. Nolan, U. Kristina Walle and Thomas Walle*

*Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of
South Carolina, Charleston, SC 29425*

Short Title: Quercetin and resveratrol inhibit EST

Correspondence and proofs:

Thomas Walle, Ph.D.
Department of Cell and Molecular Pharmacology and Experimental Therapeutics
Medical University of South Carolina
173 Ashley Avenue
P.O. Box 250505
Charleston, SC 29425

Fax (843) 792-2475
E-mail: wallet@musc.edu

Abstract

Estrogen sulfotransferase (EST) is the sole sulfotransferase expressed in normal human breast epithelial cells and has an important function in determining free estrogen hormone levels in these cells. In the present study we examined the inhibitory effect of the dietary polyphenols quercetin and resveratrol on EST activity, i.e. 17 β -estradiol (E2) sulfation. Both compounds potently inhibited recombinant human EST in a competitive fashion with K_i values of about 1 μ M. In fact, both polyphenols could serve as substrates for EST. In order to extend the studies to more physiologically relevant conditions, we examined whether inhibition of EST also occurred in the intact cultured human mammary epithelial (HME) cells. The mean baseline EST activity (E2 sulfate formation) in the HME cells was 4.4 pmol/hr/mg protein. The IC_{50} for resveratrol was very similar to that for recombinant EST, i.e. about 1 μ M. Surprisingly, quercetin was 10 times more potent in the HME cells with an IC_{50} of about 0.1 μ M, a concentration that should be possible to achieve from the normal dietary content of this flavonoid.

1. Introduction

Estrogen hormones are important for the growth and development of normal human breast tissue. The presence of estrogen, however, also is a requirement for the growth and development of most breast cancers. Although the major proportion of active estrogen in premenopausal women is produced by the ovaries, and thus requires transport to the breast tissue, an increasing proportion is synthesized in peripheral tissues, including the breast [1, 2], in postmenopausal women. Biological processes that affect the intracellular availability of estrogen hormones to their receptors will therefore influence the progression of breast cancer. This has led to the development of multiple strategies to decrease the cellular exposure and response to estrogen hormone. Two therapeutically accepted approaches to accomplish this is inhibition of estrogen action by antiestrogens, which interact with estrogen receptors [3], and inhibition of estrogen production by inhibitors of aromatase, the enzyme responsible for estrogen synthesis [4].

The intracellular levels of estrogen can also be affected by conjugating enzymes, e.g. UDP-glucuronosyl transferase [5], and in particular estrogen sulfotransferase (EST), an enzyme highly specific for 17 β -estradiol (E2) and estrone [6, 7]. Interestingly, EST has been demonstrated to be highly expressed in the normal human mammary epithelial cells, but with very low or no expression in breast cancer cells [6, 7]. A high EST expression, which can be stimulated by progesterone [8], may result in diminished estrogen hormone levels and a protective effect [6-8]. The resulting estrogen sulfates can, however, be hydrolyzed by estrogen sulfatase [2, 9]. A recent study indicated that dietary flavonoids, including quercetin, may inhibit estrogen sulfatase, suggesting a protective effect of these dietary polyphenols [10].

Previous studies have demonstrated that flavonoids can be potent inhibitors of a human sulfotransferase, P-PST [11, 12], which can sulfonate high concentrations of estrogen hormones [13]. In the present study we demonstrate very potent inhibition of EST by the polyphenols quercetin and resveratrol (Fig. 1), using both recombinant EST as well as cultured normal human mammary epithelial (HME) cells.

2. Materials and Methods

2.1. Materials

E2, quercetin, quercitrin, and resveratrol were purchased from Sigma (St. Louis, MO). [3 H]Estradiol

($[^3\text{H}]\text{E2}$) (48 Ci/mmol) and $[^{35}\text{S}]$ -labeled 3'-phosphoadenosine-5'-phosphosulfate (PAPS) (1.0 - 1.5 Ci/mmol) were purchased from DuPont-New England Nuclear (Wilmington, DE). Ultrapure PAPS was purchased from Dr. S. S. Singer (University of Dayton, Dayton, OH). Quercetin 4'-monoglucoside was purified from red onions as previously described [14].

2.2. Isolation of recombinant EST

EST cDNA subcloned into the pKK233-2 bacterial vector and expressed in *Escherichia coli* XL1-Blue strain was donated by Dr. C. N. Falany (University of Alabama at Birmingham). Recombinant human EST was isolated and purified from EST/pKK233-2 XL1-Blue cultures after induction with 1 mM isopropyl- β -D-thiogalactopyranoside for 5 h at 37°C, as previously described [15] with several modifications [16].

2.3. In vitro incubations

E2 sulfation was assayed as previously described [15] using a chloroform extraction procedure (pH 8)[17]. The reaction mixtures containing 0.01 μl human recombinant EST, 20 nM $[^3\text{H}]\text{E2}$ and 25 μM PAPS in Tris-HCl buffer, pH 7.4, with 8 mM dithiothreitol and 0.0625% BSA in a final volume of 200 μl , were incubated at 37°C for 30 min. Reactions were performed in the presence and absence of the inhibitors quercetin, quercetin 4'-monoglucoside, quercitrin, and resveratrol (0.1 - 100 μM). The reactions were terminated by adding 250 μl 0.25 M Tris.HCl buffer, pH 8.7, and 3 ml chloroform. After mixing and centrifugation, aliquots of the aqueous phase were subjected to liquid scintillation counting. To determine the mode of EST inhibition by quercetin and resveratrol, a range of $[^3\text{H}]\text{E2}$ concentrations (5 - 50 nM), as well as inhibitor concentrations (0.5 - 2 μM) were used.

2.4. Culturing of human mammary epithelial (HME) cells

Primary human mammary epithelial (HME) cells, at passage 7, were obtained from Clonetics (San Diego, CA). These cells were derived from a 22-year old healthy woman who had undergone reduction mammoplasty. Cell cultures were maintained as recommended by Clonetics [18]. Serum-free mammary epithelial growth medium was supplemented with the following (final concentrations): bovine pituitary extract (52 $\mu\text{g/ml}$), human recombinant epidermal growth factor (10 ng/ml), insulin (5 $\mu\text{g/ml}$),

hydrocortisone (0.5 $\mu\text{g/ml}$), gentamicin (50 $\mu\text{g/ml}$), and amphotericin B (50 ng/ml). Experiments were conducted with cells at passage 9-11.

2.5. *In situ* HME cell incubations

For studies of E2 sulfation in intact HME cells, cells were seeded in 6-well plates and allowed to grow to confluency (8-10 days) [18]. The cells were then incubated for 1 hr at 37°C with 20 nM [^3H]E2 in 1 ml of a HEPES-buffered balanced salt solution (HBSS) of the following composition: 10 mM glucose, 20 mM HEPES, 1.2 mM Na_2HPO_4 , 1.2 mM MgSO_4 , 145 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , and NaOH to a pH of 7.4. Incubations were performed in the presence and absence of the inhibitors quercetin and resveratrol (0 - 10 μM). 100 μl aliquots of the HBSS incubation buffer were sampled at various times and E2 sulfate formation was assayed as previously described [15] using the alkaline-chloroform extraction procedure [17].

2.6. *Sulfation of quercetin and resveratrol*

EST-catalyzed sulfation of quercetin and resveratrol was determined using the previously described ion-pair extraction method [19]. The typical reaction mixture contained 0.1 - 10 μM of the polyphenol substrate, 1 μM [^{35}S]PAPS and 0.1 μl of recombinant EST in 33 mM Tris.HCl buffer, pH 7.4, with 8 mM dithiothreitol and 0.0625% BSA in a total volume of 100 μl . The samples were incubated for 30 min at 37°C and the reactions were terminated by the addition of 10 μl 2.5% acetic acid, 20 μl of 0.1 M tetrabutylammonium hydrogen sulfate and 500 μl ethyl acetate. After mixing and centrifugation, 400 μl of the ethyl acetate extract was subjected to liquid scintillation counting.

2.7. *Data Analysis*

K_m values were derived with UltraFit (Biosoft, Cambridge, UK) from V vs. S plots, using the Michaelis-Menten equation [20]. The IC_{50} values for the concentration-activity curves from individual experiments were derived with UltraFit, using an equation for double exponential decay with offset. The mode of quercetin and resveratrol inhibition of E2 sulfation by recombinant EST and its K_i values were derived graphically from Lineweaver-Burk plots (1/V vs. 1/S) and replots of the slope vs. inhibitor

concentration [21].

3. Results

The recombinant human EST was isolated as described [15] and characterized catalytically with its main natural substrate E2. The formation of E2 sulfate had an apparent K_m value of 21 nM. Saturating concentrations of the co-substrate PAPS were reached at 10 μ M.

The sulfation of E2 by recombinant EST was inhibited potently by quercetin, yielding an IC_{50} value of 1.4 μ M. The naturally occurring glycosides of quercetin, i.e. quercetin 4'-glucoside and quercitrin (quercetin 3-rhamnoside) were considerably less potent, with estimated IC_{50} values of about 30 μ M, Fig. 2A. Resveratrol had a potency very similar to that of quercetin with an IC_{50} value of 1.6 μ M, Fig. 2B.

To determine the mode of inhibition, varying concentrations of quercetin and resveratrol were used (0.5 – 2 μ M) together with varying concentrations of the substrate E2 (5 – 50 nM). As shown in Fig. 3A and B, both quercetin and resveratrol appeared to be competitive inhibitors of E2 sulfation. The K_i values, although somewhat lower than the IC_{50} values in Fig. 2, were very similar for quercetin and resveratrol, 0.58 and 0.36 μ M, respectively.

The finding that the inhibition was competitive suggested that both quercetin and resveratrol are substrates for the human EST. This was tested using an ion-pair extraction method [19], particularly suitable for labile sulfate conjugates. The data shown in Fig. 4A and B clearly demonstrated that both quercetin and resveratrol are sulfated, with apparent K_m values of 0.32 and 0.53 μ M, respectively, i.e. very similar to their K_i values for inhibition of E2.

To determine the potential physiological significance of EST inhibition by quercetin and resveratrol, experiments were carried out in cultured intact human mammary epithelial (HME) cells. These cells have previously been shown to express high EST activity [6, 18]. The mean baseline EST activity of the HME cells in these experiments was 4.4 pmol of E2 sulfate formed per hr and mg protein, using 20 nM E2. Surprisingly, the quercetin inhibition of E2 sulfation in the intact HME cells was more potent than by recombinant EST, yielding an IC_{50} value as low as 0.13 μ M, Fig. 5A. Complete inhibition occurred at 1 μ M quercetin. For resveratrol, the inhibition was similar to that observed with recombinant EST, resulting in an IC_{50} value of 1.3 μ M, Fig. 5B.

4. Discussion

Quercetin and resveratrol demonstrated very similar inhibition of the catalytic activity of the recombinant human EST with an IC_{50} value of about 1 μM , whereas two of the naturally occurring glycosides of quercetin were about 30 times less potent. Interestingly, the inhibition by both quercetin and resveratrol appeared to be simply a competitive type of interaction. Therefore, as expected, both of these dietary components were substrates for EST, with K_m values similar to their K_i values for inhibition of E2 sulfation. This finding is interesting in that P-PST, the most ubiquitous of the human STs, responsible for the sulfation of most foreign phenolic compounds [22] and highly related to EST [15], does not appear to use quercetin as a substrate [12].

Quercetin has previously been shown to also inhibit the catalytic activity of P-PST with an IC_{50} value as low as 0.1 μM [11, 12]. This inhibition was noncompetitive in nature. In the intact human hepatoma cell line Hep G2, which has P-PST expression similar to the human liver [23], the potency of quercetin inhibition of P-PST decreased about 25-fold, yielding an IC_{50} value of 2.5 μM [12]. This was speculated to be due to a combination of factors, including poor plasma membrane penetrability as well as extensive metabolism of quercetin. This was thought to be consistent with the generally held view that flavonoids have a low cellular availability.

The very potent inhibitory effect of quercetin on the sulfation of estradiol by EST in the intact HME cells is therefore most surprising. Thus, quercetin is 25 times more potent inhibiting the EST activity in these cells than inhibiting the P-PST activity in Hep G2 cells, even though quercetin is 10 times less potent inhibiting recombinant EST than P-PST. The mechanism for this potent inhibition is unclear. It could involve 1) a mechanism concentrating quercetin inside the breast cell, 2) bioactivation to a more potent form, e.g., by O-methylation [24, 25], 3) inhibition of synthesis of the cofactor PAPS, or perhaps most likely, 4) inhibition of some signaling pathway important for the regulation of EST expression. The IC_{50} of 0.1 μM corresponds to a quercetin concentration of about 30 ng/ml, which is 5-10 times lower than concentrations in plasma reported in humans after consuming common foodstuffs rich in quercetin, such as onions and apples [26]. Even when taking into account the high plasma binding of quercetin [27], this potent effect on EST function in the breast cell may be relevant in humans.

Even though inhibition of EST by quercetin, resulting in elevated estrogen hormone levels in the normal breast cell, may be a potentially harmful effect, other considerations may be of importance. In a recent study, it was demonstrated, also in the HME cells, that EST could catalyze the bioactivation of the cooked-food mutagen and procarcinogen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (N-OH-PhIP) and its subsequent binding to genomic DNA [18]. This potential breast cancer initiating reaction was highly correlated to EST expression. Thus, inhibiting EST with quercetin and other dietary flavonoids could serve as a protective mechanism in breast cancer initiation. Although inhibition of EST may increase circulating levels of estradiol, quercetin has been shown to compete with a similar affinity as E2 for Type II estrogen binding sites [28]. The interaction of quercetin at these sites serves to inhibit the estradiol induction of cellular proliferation [28-31]. Therefore, as quercetin may increase mean estradiol concentration by inhibiting EST, this potentially harmful effect may be countered by the opposing, growth inhibitory, action of quercetin at the type II estrogen binding sites.

Acknowledgments

This research was supported by the National Institutes of Health grant CA69138.

References

- [1] Yue, W., Wang, J.-P., Hamilton, C.J., Demers, L.M., Santen, R.J., In situ aromatization enhances breast tumor estradiol levels and cellular proliferation, *Cancer Res.* 58 (1998) 927-932.
- [2] Pasqualini, J.R., Cortes-Prieto, J., Chetrite, G., Talbi, M., Ruiz, A., Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma, *Int. J. Cancer* 70 (1997) 639-643.
- [3] Osborne, C.K., Tamoxifen in the treatment of breast cancer, *New Engl. J. Med.* 339 (1998) 1609-1618.
- [4] Brodie, A.M.H., Njar, V.C.O., Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications, *J. Steroid Biochem. Molec. Biol.* 66 (1998) 1-10.
- [5] Adams, J.B., Phillips, N.S., Young, C.E., Formation of glucuronides of estradiol-17 β by human mammary cancer cells, *J. Steroid Biochem.* 33 (1989) 1023-1025.
- [6] Falany, J.L., Falany, C.N., Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines, *Cancer Res.* 56 (1996) 1551-1555.
- [7] Qian, Y., Deng, C., Song, W.-C., Expression of estrogen sulfotransferase in MCF-7 cells by cDNA transfection suppresses the estrogen response: Potential role of the enzyme in regulating estrogen-dependent growth of breast epithelial cells, *J. Pharmacol. Exp. Ther.* 286 (1998) 555-560.
- [8] Falany, J.L., Falany, C.N., Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone, *Endocrinology* 137 (1996) 1395-1401.
- [9] Purohit, A., Vernon, K.A., Wagenaar Hummelinck, A.E., Woo, L.W.L., Hejaz, H.A.M., Potter, B.V.L., Reed, M.J., The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphotase inhibitors with reduced oestrogenicity, *J. Steroid Biochem. Molec. Biol.* 64 (1998) 269-275.
- [10] Huang, Z., Fasco, M.J., Kaminsky, L.S., Inhibition of estrone sulfatase in human liver microsomes by quercetin and other flavonoids, *J. Steroid Biochem. Molec. Biol.* 63 (1997) 9-15.
- [11] Walle, T., Eaton, E.A., Walle, U.K., Quercetin, a potent and specific inhibitor of the human P-form phenolsulfotransferase, *Biochem. Pharmacol.* 50 (1995) 731-734.

- [12] Eaton, E.A., Walle, U.K., Lewis, A.J., Hudson, T., Wilson, A.A., Walle, T., Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase: potential role in drug metabolism and chemoprevention, *Drug Metab. Dispos.* 24 (1996) 232-237.
- [13] Hernández, J.S., Watson, R.W.G., Wood, T.C., Weinshilboum, R.M., Sulfation of estrone and 17 β -estradiol in human liver: Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase, *Drug Metab. Dispos.* 20 (1992) 413-422.
- [14] Walgren, R.A., Walle, U.K., Walle, T., Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells, *Biochem. Pharmacol.* 55 (1998) 1721-1727.
- [15] Falany, C.N., Krasnykh, V., Falany, J.L., Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase, *J. Steroid Biochem. Molec. Biol.* 52 (1995) 529-539.
- [16] Lewis, A.J., Kelly, M.M., Walle, U.K., Eaton, E.A., Falany, C.N., Walle, T., Improved bacterial expression of the human P form phenolsulfotransferase: Applications to drug metabolism, *Drug Metab. Dispos.* 24 (1996) 1180-1185.
- [17] Falany, C.N., Vazquez, M.E., Kalb, J.M., Purification and characterization of human liver dehydroepiandrosterone sulphotransferase, *Biochem. J.* 260 (1989) 641-646.
- [18] Lewis, A.J., Walle, U.K., King, R.S., Kadlubar, F.F., Falany, C.N., Walle, T., Bioactivation of the cooked food mutagen *N*-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells, *Carcinogenesis* 19 (1998) 2049-2053.
- [19] Varin, L., Barron, D., Ibrahim, R.K., Enzymatic assay for flavonoid sulfotransferase, *Anal. Biochem.* 161 (1987) 176-180.
- [20] Segel, I.H., *Graphical determination of K_m and V_{max}* , in *Enzyme Kinetics*. 1975, John Wiley & Sons: New York. p. 44-54.
- [21] Cleland, W.W., The kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition: nomenclature and theory, *Biochim. Biophys. Acta* 67 (1963) 173-187.
- [22] Falany, C.N., Sulfation and sulfotransferases 3: Enzymology of human cytosolic sulfotransferases, *FASEB J.* 11 (1997) 206-216.
- [23] Shwed, J.A., Walle, U.K., Walle, T., Hep G2 cell line as a human model for sulphate conjugation of

drugs, *Xenobiotica* 22 (1992) 973-982.

- [24] Zhu, B.T., Ezell, E.L., Liehr, J.G., Catechol-*O*-methyltransferase-catalyzed rapid *O*-methylation of mutagenic flavonoids - metabolic inactivation as a possible reason for their lack of carcinogenicity *in vivo*, *J. Biol. Chem.* 269 (1994) 292-299.
- [25] Boulton, D.W., Walle, U.K., Walle, T., Fate of the flavonoid quercetin in human cell lines: Chemical instability and metabolism, *J. Pharm. Pharmacol.* 51 (1999) 353-359.
- [26] Hollman, P.C.H., van Trijp, J.M.P., Buysman, M.N.C.P., v.d. Gaag, M.S., Mengelers, M.J.B., de Vries, J.H.M., Katan, M.B., Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man, *FEBS Lett.* 418 (1997) 152-156.
- [27] Boulton, D.W., Walle, U.K., Walle, T., Extensive binding of the bioflavonoid quercetin to human plasma proteins, *J. Pharm. Pharmacol.* 50 (1998) 243-249.
- [28] Piantelli, M., Maggiano, N., Ricci, R., Larocca, L.M., Capelli, A., Scambia, G., Isola, G., Natali, P.G., Ranelletti, F.O., Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells, *J. Invest. Dermatol.* 105 (1995) 248-253.
- [29] So, F.V., Guthrie, N., Chambers, A.F., Carroll, K.K., Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen, *Cancer Lett.* 112 (1997) 127-133.
- [30] Caltagirone, S., Ranelletti, F.O., Rinelli, A., Maggiano, N., Colasante, A., Musiani, P., Aiello, F.B., Piantelli, M., Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer, *Am. J. Respir. Cell Mol. Biol.* 17 (1997) 51-59.
- [31] Markaverich, B.M., Alejandro, M.A., Bioflavonoids, type II [³H]estradiol binding sites and prostatic cancer cell proliferation, *Int. J. Oncol.* 11 (1997) 1311-1319.

Legends for Figures

Fig. 1. Chemical structures of the dietary polyphenols quercetin and resveratrol


Fig. 2. Inhibition of E2 sulfation by A. quercetin (○), quercetin 4'-monoglucoside (●) and quercitrin (Δ) and B. resveratrol, using recombinant human EST. Experiments are means $\pm$ SEM (N = 3). For some points the error bars are smaller than the symbols.

Fig. 3. Inhibition of E2 sulfation by A. quercetin and B. resveratrol, using recombinant EST. In these double reciprocal plots of velocity versus substrate concentration the inhibitor concentrations used were 0 (■), 0.5 (□), 1 (●) and 2 (○) μ M. The E2 concentrations used were 5 – 50 nM. The data represent mean values of two experiments.


Fig. 4. EST-Catalyzed sulfation of A. quercetin and B. resveratrol. The data represent mean values of two determinations.

Fig. 5. Inhibition of E2 sulfation by A. quercetin and B. resveratrol in the cultured intact HME cells. The cells were incubated for 3 hr with [3 H]E2 in the absence and presence of varying concentrations of inhibitor. [3 H]E2 sulfate was then measured in the medium. The data shown represent mean $\pm$ SEM of three experiments. For some points the error bars are smaller than the symbols.

FIGURE 1



Resveratrol



Quercetin

FIGURE 2





FIGURE 3

A.



B.






FIGURE 4


A.



B.



A.



B.




FIGURE 5

INHIBITION OF ESTROGEN SULFOTRANSFERASE IN NORMAL HUMAN MAMMARY EPITHELIAL CELLS. A.L. Nolan, Y. Otake, U.K. Walle, and T. Walle. *Medical University of South Carolina, Charleston, SC 29425.*

Cooked-food mutagens have recently been suggested to contribute to the etiology of breast cancer. 2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP), the most prevalent mutagen in the Western diet, is not carcinogenic until it is bioactivated by enzymes in the body. Previous observations have demonstrated that estrogen sulfotransferase (EST), present in normal human mammary epithelial (HME) cells, is a critical enzyme necessary for the bioactivation and subsequent DNA binding of N-hydroxylated PhIP (N-OH-PhIP) (*Carcinogenesis*, **19**: 2049-2053, 1998). Breast cancer initiation by this mechanism may be preventable. As naturally occurring phenols, present in our diet, have previously been shown to inhibit P-form phenol sulfotransferase (*Drug Metab. Dispos.*, **24**: 232-237, 1996), the objective of this study was to examine the inhibitory effect of two dietary phenols, quercetin and resveratrol, on EST activity. Both compounds potently inhibited recombinant EST in a competitive fashion with K_i values of 1 μM . To extend these studies to more physiologically relevant conditions the inhibition of EST was examined in intact cultured HME cells. The mean baseline EST activity in the HME cells was 4.4 pmol/hr/mg protein. The IC_{50} for resveratrol was very similar to that for recombinant EST, i.e. about 1 μM . Surprisingly, quercetin was ten times more potent in the HME cells with an IC_{50} of about 0.1 μM , a concentration that should be possible to achieve from the normal dietary content of this polyphenol. Supported by CA69138.